Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

Cellosaurus SK-N-MC (CVCL_0530)

[Text version]
Cell line name SK-N-MC
Accession CVCL_0530
Resource Identification Initiative To cite this cell line use: SK-N-MC (RRID:CVCL_0530)
Comments Problematic cell line: Misclassified. Originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor (PubMed=20143388).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: ENCODE project common cell types; tier 3.
From: Memorial Sloan Kettering Cancer Center; New York; USA.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00267.
Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 776.
Population: Caucasian.
Doubling time: 32 hours (PubMed=4748425); 23 hours (PubMed=24312454); ~32 hours (CLS=300340); ~48 hours (DSMZ=ACC-203).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Orbital region; UBERON=UBERON_0004088.
Sequence variations
  • Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=7591257; PubMed=8040301; PubMed=25010205).
  • Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (PubMed=19787792; PubMed=26428435).
HLA typing Source: PubMed=26589293
Class I
Class II
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0
East Asian, North0.61
East Asian, South0
South Asian0.27
European, North67.85
European, South29.43
Disease Askin tumor (NCIt: C7542)
Peripheral primitive neuroectodermal tumor (ORDO: Orphanet_370348)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
Sex of cell Female
Age at sampling 12Y
Category Cancer cell line
STR profile Source(s): ATCC=HTB-10; CCRID; CLS=300340; COG; DSMZ=ACC-203; KCLB=30010; PubMed=19787792; PubMed=24312454; PubMed=25010205; PubMed=30879952

D3S135815 (ATCC=HTB-10; CLS=300340; KCLB=30010; PubMed=19787792; PubMed=30879952)
15,16 (CCRID; DSMZ=ACC-203; PubMed=24312454; PubMed=25010205)
D18S5113,14 (ATCC=HTB-10; CCRID; CLS=300340; DSMZ=ACC-203; PubMed=24312454; PubMed=25010205)
14 (PubMed=19787792)
D19S43313,15.2 (ATCC=HTB-10; CCRID; PubMed=19787792; PubMed=24312454; PubMed=25010205)
13,16 (DSMZ=ACC-203)
D21S1130,31.2 (ATCC=HTB-10; CLS=300340; COG; DSMZ=ACC-203; PubMed=19787792; PubMed=24312454; PubMed=25010205)
30,31.2,32.2 (CCRID)
Penta D8,9,13 (DSMZ=ACC-203)
9,13 (ATCC=HTB-10; CLS=300340)
Penta E16,18
TPOX9,11 (ATCC=HTB-10; CCRID; CLS=300340; COG; DSMZ=ACC-203; KCLB=30010; PubMed=24312454; PubMed=25010205; PubMed=30879952)
11 (PubMed=19787792)

Run an STR similarity search on this cell line
Web pages http://genome.ucsc.edu/encode/protocols/cell/human/SK-N-MC_protocol.pdf

Biedler J.L., Helson L., Spengler B.A.
Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture.
Cancer Res. 33:2643-2652(1973)

Biedler J.L.
Chromosome abnormalities in human tumor cells in culture.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975)

PubMed=62055; DOI=10.1093/jnci/57.3.683
Biedler J.L., Spengler B.A.
A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture.
J. Natl. Cancer Inst. 57:683-695(1976)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

Biedler J.L., Roffler-Tarlov S., Schachner M., Freedman L.S.
Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.
Cancer Res. 38:3751-3757(1978)

Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.
Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant.
Cancer Res. 42:1331-1336(1982)

Biedler J.L., Meyers M.B., Spengler B.A.
Homogeneously staining regions and double minute chromosomes, prevalent cytogenetic abnormalities of human neuroblastoma cells.
(In) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York (1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2987426; DOI=10.1007/BF00165170
Helson L., Helson C.
Human neuroblastoma cells and 13-cis-retinoic acid.
J. Neurooncol. 3:39-41(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2784858; DOI=10.1073/pnas.86.8.2804
Knuth A., Wolfel T., Klehmann E., Boon T., Meyer zum Buschenfelde K.-H.
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989)

Kovar H., Auinger A., Jug G., Aryee D.N.T., Zoubek A., Salzer-Kuntschik M., Gadner H.
Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours.
Oncogene 8:2683-2690(1993)

Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994)

PubMed=8040301; DOI=10.1172/JCI117360
Giovannini M., Biegel J.A., Serra M., Wang J.-Y., Wei Y.-L.H., Nycum L., Emanuel B.S., Evans G.A.
EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.
J. Clin. Invest. 94:489-496(1994)

PubMed=7591257; DOI=10.1002/ijc.2910630407
Ida K., Kobayashi S., Taki T., Hanada R., Bessho F., Yamamori S., Sugimoto T., Ohki M., Hayashi Y.
EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor.
Int. J. Cancer 63:500-504(1995)

van Weering D.H.J., Medema J.P., van Puijenbroek A.A.F.L., Burgering B.M.T., Baas P.D., Bos J.L.
Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells.
Oncogene 11:2207-2214(1995)

PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X
Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Hum. Pathol. 27:408-416(1996)

PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4
Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.
The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
Cancer Lett. 104:183-192(1996)

PubMed=9121763; DOI=10.1038/sj.onc.1200911
van Puijenbroek A.A.F.L., van Weering D.H.J., van den Brink C.E., Bos J.L., van der Saag P.T., de Laat S.W., den Hertog J.
Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation.
Oncogene 14:1147-1157(1997)

PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=15390183; DOI=10.1002/gcc.20096
Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.
Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
Genes Chromosomes Cancer 41:297-308(2004)

PubMed=18160777; DOI=10.1159/000109614
Savola S., Nardi F., Scotlandi K., Picci P., Knuutila S.
Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma.
Cytogenet. Genome Res. 119:21-26(2007)

PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=21822310; DOI=10.1038/onc.2011.317
Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V., Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R., Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U., Debiec-Rychter M., Schaefer K.-L., de Alava E.
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Oncogene 31:1287-1298(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=24312454; DOI=10.1371/journal.pone.0080060
May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L., Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.
PLoS ONE 8:E80060-E80060(2013)

PubMed=25010205; DOI=10.1371/journal.pgen.1004475
Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S., Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y., Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H., Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S., Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.
The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation.
PLoS Genet. 10:E1004475-E1004475(2014)

PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622
Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A., Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S., Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O., Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M., Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V., Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A., Zhang J.-H., Delattre O.
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Cancer Discov. 4:1342-1353(2014)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020
Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P., Schmidt T., Szuhai K., Hogendoorn P.C.W.
CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
Eur. J. Cancer 51:2624-2633(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014
Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C., Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J., Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N., Muller I., Walles H., Hartmann W., Rossig C.
EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells.
Mol. Ther. 27:933-946(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

Orth M.F.
Systematic multi-omics profiling of Ewing sarcoma cell lines.
Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany

Cell line collections (Providers) ATCC; HTB-10
CLS; 300340
ECACC; 90022302
KCB; KCB 2012033YJ
KCLB; 30010
NCBI_Iran; C535
Cell line databases/resources CLO; CLO_0009058
MCCL; MCC:0000429
CLDB; cl4338
CLDB; cl4339
CLDB; cl4340
CLDB; cl4341
CLDB; cl4342
CLDB; cl4343
cancercelllines; CVCL_0530
CCRID; 1101HUM-PUMC000263
Cell_Model_Passport; SIDM00634
DepMap; ACH-000039
DSMZCellDive; ACC-203
Lonza; 82
TOKU-E; 3148
Anatomy/cell type resources BTO; BTO:0002914
Biological sample resources 4DN; 4DNSRW6BI5JA
BioSample; SAMN01821666
BioSample; SAMN03151999
BioSample; SAMN10987896
CRISP screens repositories BioGRID_ORCS_Cell_line; 462
Chemistry resources ChEMBL-Cells; CHEMBL3307551
ChEMBL-Targets; CHEMBL614163
PharmacoDB; SKNMC_1408_2019
PubChem_Cell_line; CVCL_0530
Encyclopedic resources Wikidata; Q54954478
Experimental variables resources EFO; EFO_0002860
Gene expression databases ArrayExpress; E-MTAB-2770
GEO; GSM393038
GEO; GSM510009
GEO; GSM824868
GEO; GSM824869
GEO; GSM887596
GEO; GSM888679
GEO; GSM945247
GEO; GSM945264
GEO; GSM1022638
GEO; GSM1676318
GEO; GSM1701651
Polymorphism and mutation databases Cosmic; 753613
Cosmic; 897448
Cosmic; 922655
Cosmic; 1078367
Cosmic; 1078391
Cosmic; 1082511
Cosmic; 1084314
Cosmic; 2228233
Cosmic; 2250468
Cosmic; 2301579
IARC_TP53; 23586
LiGeA; CCLE_596
Progenetix; CVCL_0530
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number44